Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAYHIA: Phase 3 randomized double-blind trial of ianalumab in warm autoimmune hemolytic anemia
2022-001773-31Phase 3Active
- Sponsor
- Novartis
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in warm autoimmune hemolytic anemia (wAIHA) comparing Ianalumab with Placebo (2 arms). Primary endpoint: Durable response (binary). Started Oct 2022; status: active.
02
Drugs
ianalumab
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on 2022-001773-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001773-31.